-
A new generation of anti-flu drugs!
Time of Update: 2021-12-09
According to information on Zhengxiang's official website, ZX-7101A is a new generation of oral anti-influenza drug independently developed by the company .
Retrieved Nov 1, 2021, from http:// The clinical trial application of Zhengxiang Medicine's new anti-influenza drug ZX-7101A was officially approved by NMPA.
-
World Acromegaly Day: ASO drugs show efficacy
Time of Update: 2021-12-09
newsnewsToday ASO manufacturer Ionis announced a phase II clinical result of acromegaly of its liver-targeted growth hormone receptor (GHR) trans-nucleic acid drug Cemdelirsen (IONIS-GHR-L) .
The results of placebo, low and high dose groups were 141 days of blood growth hormone binding protein (GHBP).
-
The KRAS G12C inhibitor imported by Zai Lab exceeds RMB 300 million for clinical application
Time of Update: 2021-12-09
Article source: Medical Rubik's Cube InfoAuthor: Shi BeiOn November 1, the CDE official website showed that the clinical application of Mirati/Zai Lab's highly selective and potent oral KRAS G12C small molecule inhibitor MRTX849 tablets (adagrasib) was officially accepted by the State Food and Drug Administration .
-
Sichuan pharmaceutical companies attack $12 billion star antineoplastic drug
Time of Update: 2021-12-09
According to data from Meinenet, the global sales of lenalidomide capsules in 2020 will exceed 12 billion U.
S. dollars; the terminal sales of public medical institutions in China will exceed 1 billion .
In 2020, the global sales of this product exceeded 12 billion U.
-
The review date of Legendary Bio's BCMA CAR-T cell therapy was postponed by the U.S. FDA for 3 months
Time of Update: 2021-12-09
In a brief statement, Nanjing Legend and Yang Sen stated that the postponement is to "enough time to review information on an updated analytical method following a recent FDA information request .
-
Kras/PD-1 combined first-line lung cancer debut
Time of Update: 2021-12-09
newsnewsToday Mirati announced some data from its Kras inhibitor adagrasib and Merck’s K drug combination in a 1b clinical trial called KRYSTAL-1 .
Kras inhibitors have a larger therapeutic window for patients with Kras variant tumors, so the combination with K drugs may be better tolerated .
-
After Zhong Suansui, can the 9-valent HPV vaccine recreate the richest man in China?
Time of Update: 2021-12-09
At present, the fastest domestic 9-valent HPV vaccine research and development progress is in clinical phase III, and there are 4 companies in this phase, namely Bowei Biotechnology, Wantai Biotechnology, Kangleweishi and Ruike Biotechnology, and vaccine companies before Phase III Although there are many, there is a high probability that they will miss the "first prize" .
-
Menarini receives FDA orphan drug designation for acute myeloid leukemia drug
Time of Update: 2021-12-09
gov number NCT03008187) is the first human phase I/II dose upgrade and cohort expansion trial of SEL24/MEN1703, and it was studied as a single agent for the treatment of patients with relapsed/refractory AML .
-
Cefprozil API, a wholly-owned subsidiary of Guobang Pharmaceutical, obtained CEP certificate
Time of Update: 2021-12-09
Cefprozil is a second-generation broad-spectrum cephalosporin drug.
The biggest feature of cefprozil is that it is safe to use and can be administered orally, making it a first-line anti-infective drug for children .
-
BeiGene introduced over 100 million U.S. dollars!
Time of Update: 2021-12-09
ArticleMedicine GuanlanRecently, the Chinese drug clinical trial registration and information disclosure platform showed that BeiGene has launched a phase 3 study of zanidatamab (ZW25) in China for the first-line treatment of advanced HER2-positive gastroesophageal adenocarcinoma .
-
The implementation rules for the management of Chinese medicine formula granules are issued in many places. A large number of Chinese medicines are included in the medical insurance
Time of Update: 2021-12-09
With the advancement of the time for traditional Chinese medicine formula granules to enter the medical insurance, all provinces have begun to act01 A large number of drugs will be included in medical
-
The first imitation of Haisco's "ranolazine sustained-release tablets" was launched
Time of Update: 2021-12-09
Source: CDE official websiteRanolazine was developed by Gilead and is the first drug approved by the FDA for the treatment of chronic angina pectoris in the past decade.
It was approved for marketing in the United States in 2006 for the first-line treatment of symptomatic patients with chronic angina pectoris .
-
The "three high" drugs are here for purchase!
Time of Update: 2021-12-09
On November 5th, the Henan Provincial Medical Insurance Bureau issued the "Announcement on the Procurement of Drug Alliance of the 13 Provinces (Cities, Districts, and Corps) of Henan, Mongolia, Jiangxi, Jiangxi, Guangdong, Guiyu, Yunnan, Shaanxi, Qingning, and Ningxin Corps (1)", announcing the "Relevant drugs are purchased in quantity .
-
Competition in the PI3K inhibitor market has increased
Time of Update: 2021-12-09
A few days ago, Incyte announced that the FDA has accepted a new generation of phosphatidylinositol 3-kinase delta (PI3K delta) inhibitor parsaclisib for the treatment of relapsed or refractory follicular lymphoma (FL), marginal zone lymphoma (MZL) and mantle cell lymphoma New Drug Application (NDA) for Type 3 Non-Hodgkin’s Lymphoma (MCL) .
-
Boehringer Ingelheim and King's College London join forces to advance new treatment concepts for major depression and schizophrenia
Time of Update: 2021-12-09
Ingelheim, Germany and London, England, November 3, 2021/PRNewswire/ - Boehringer Ingelheim and the Institute of Psychiatry, Psychology and Neuroscience (IoPPN) at King's College London announced a new collaboration on September 27 , The collaboration focused on understanding the brain circuit dysfunction of major depression (MDD) and schizophrenia (SZ), which can lead to cognitive impairment in patients .
-
【Big Data Perspective】The innovation pattern of China's biopharmaceuticals
Time of Update: 2021-12-09
Figure 2 Distribution of innovative biological drug treatment fields declared in 2016-2020 (according to generic names)Approval pattern of innovative biopharmaceuticals in ChinaFigure 3 shows the changes in the number of generic names of innovative biopharmaceuticals approved by China and the United States .
-
Multinational pharmaceutical companies release third-quarter financial reports: Pfizer and Merck have outstanding performance
Time of Update: 2021-12-08
534 billion; sales of GARDASIL/GARDASIL 9 (HPV vaccine) increased by 68% year-on-year to US$1.
Among them, the total revenue of Roche Diagnostics in the first three quarters increased by 38% year-on-year to 13.
-
Nearly 50,000 fined OTC pharmacies for overdue sales
Time of Update: 2021-12-08
In case of selling inferior drugs, the illegal income from the sale shall be confiscated, and a fine of ten to twenty times the value of the illegally sold drugs shall be imposed; if the value of the illegally retailed drugs is less than 10,000 yuan, it shall be calculated as 10,000 yuan .
-
Heavy document is released, "API-preparation integration" enterprises welcome bright moments
Time of Update: 2021-12-08
In the past 5-10 years, the leading intermediates and API companies have been The quality management, cost control and other advantages accumulated in the process of expanding and regulating the market will help relevant companies to enrich their product structure in the medium term, and achieve forward integration and business model expansion along the industrial chain .
-
The chronic disease drug market is huge, and a large number of pharmaceutical companies are accelerating their deployment in this field
Time of Update: 2021-12-08
On the whole, in the field of chronic disease management, cooperation between pharmaceutical companies and Internet medical companies is becoming more and more common.
